Last checked at 
| Thursday 23 November | |
| abrdn UK Smaller Companies Growth Trust PLC | AGM |
| Avation PLC | AGM |
| Bradda Head Lithium Ltd | AGM |
| DX Group PLC | AGM |
| Europa Oil & Gas Holdings PLC | AGM |
| Fiske PLC | AGM |
| JPMorgan UK Smaller Cos Investment Trust PLC | AGM |
| Hotel Chocolat Group PLC | AGM |
| Pacific Horizon Investment Trust PLC | AGM |
| Pan African Resources PLC | AGM |
| PZ Cussons PLC | AGM |
| Rosslyn Data Technologies PLC | AGM |
| Friday 24 November | |
| Base Resources Ltd | AGM |
| Cloudbreak Discovery PLC | AGM |
| Esken Ltd | EGM re Esken Renewables disposal |
| Neometals Ltd | AGM |
| Sovereign Metals Ltd | AGM |
| Sylvania Platinum Ltd | AGM |
| Monday 27 November | |
| Chelverton Growth Trust PLC | GM re voluntary liquidation |
| European Smaller Cos Trust PLC | AGM |
| JPMorgan Global Emerging Markets Income Trust PLC | AGM |
| Quadrise PLC | AGM |
| Tribal Group PLC | GM re cash offer by Tiger Bidco 1 Ltd |
| Tuesday 28 November | |
| Bluefield Solar Income Fund Ltd | AGM |
| London Finance & Investment Group PLC | AGM |
| Nanoco Group PLC | AGM |
| Oakley Capital Investments Ltd | AGM |
| Wednesday 29 November | |
| Artemis Resources Ltd | AGM |
| Aura Energy Ltd | AGM |
| Contango Holdings PLC | AGM |
| CVS Group PLC | AGM |
| Fidelity Asian Values PLC | AGM |
| Ikigai Ventures Ltd | AGM |
| Panthera Resources PLC | AGM |
| Reconstruction Capital II Ltd | AGM |
| Renishaw PLC | AGM |
| RiverFort Global Opportunities PLC | AGM |
| Sabien Technology Group PLC | AGM |
| Scancell Holdings PLC | AGM |
| Seeing Machines Ltd | AGM |
| SLF Realisation Fund Ltd | AGM |
| Target Healthcare REIT PLC | AGM |
| Thor Energy PLC | AGM |
| Transense Technologies PLC | AGM |
| Vast Resources PLC | AGM |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. | |
18 Sep 2015 09:23
Bigger loss but positive drug trial results for Scancell Holdings
(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials
Read more